계산생물학 시장 보고서 : 용도별, 서비스별, 최종 용도별, 지역별(2025-2033년)

The global computational biology market size reached USD 6.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 32.2 Billion by 2033, exhibiting a growth rate (CAGR) of 17.83% during 2025-2033. The market is being driven by the rising number of clinical studies, along with integration of advanced technologies. At present, North America holds the largest market share, driven by the presence of leading pharmaceutical and biotechnology companies and various collaborations among companies.

Computational biology, also known as bioinformatics, is the interdisciplinary branch of science that uses math, statistics and computer science for understanding and modeling the structures and processes of life. It involves various aspects of biology, such as genetics, evolution, cell biology, and biochemistry. The process uses computational techniques, including algorithms, to represent and simulate biological systems and interpret experimental data on a large scale. Computational biology also helps understand the treatment for diseases and cellular function by creating a database of biological information from amino-acid sequences, nucleotides, and macromolecular structures. Nowadays, computational biology has become an essential part of biological research projects, including the human genome project, protein data banks and genomic databases.

Computational Biology Market Trends:

The global computational biology market is primarily driven by the rising number of clinical studies in the field of pharmacogenomics. This has helped increase the understanding of the diverse biological makeup of the patient population, biological pathways, and the genomes underpinning them. As a result, there is a high demand for computational biology solutions, as they help reduce the overall time needed for drug discovery and various other scientific experiments. The process also aids the visualization of tools to simulate advanced drug-drug interactions. In addition to this, the growing demand for computational biology in epi-genomics, proteomics, and meta-genomics to undertint protein structures and interactions is also propelling the market growth. Furthermore, various technological advancements in drug development and disease modeling, along with increasing investments by private and government organizations in research and development (R&D) activities, are also anticipated to provide a positive thrust to the market in the near future.

Key Market Segmentation:

Breakup by Application:

• Cellular and Biological Simulation
  • Computational Genomics
  • Computational Proteomics
  • Pharmacogenomics
  • Others
• Drug Discovery and Disease Modelling
  • Target Identification
  • Target Validation
  • Lead Discovery
  • Lead Optimization
• Preclinical Drug Development
  • Pharmacokinetics
  • Pharmacodynamics
• Clinical Trials
  • Phase I
  • Phase II
  • Phase III
• Human Body Simulation Software

Cellular and biological simulation accounts for the majority of the market share

Researchers can better comprehend basic biological processes and the course of disease by using cellular and biological modeling. Cellular simulations are essential to drug discovery because they allow for virtual chemical screening, drug interaction prediction, and lead candidate optimization. As a result, this reduces the time and cost associated with traditional experimental approaches. The accuracy and dependability of cellular and biological simulations are improved by the development of complex simulation software and algorithms such as agent-based modeling and systems biology techniques. A thorough grasp of biological activities is made possible by the integration of simulations with proteomic, metabolomic, and genomic data.

Breakup by Services:

• In-house
• Contract

Contract holds the largest share of the industry

Contract services provide cost-effective solutions compared to maintaining in-house capabilities, particularly for smaller companies or those with limited resources. This trend is fostering more organizations to engage third-party providers for computational biology services. Contract service providers usually have access to the latest computational tools, technologies, and methodologies that allow clients to benefit from state-of-the-art solutions without the need for significant investment in infrastructure. Furthermore, contract services offer flexibility and scalability that allow companies to adjust the level of support based on project requirements.

Breakup by End Use:

• Academics
• Pharmaceutical Industry
• Commercial

Commercial represents the leading market segment

The creation of novel treatments is becoming a top priority for commercial enterprises, necessitating the use of sophisticated computational tools for biological system modeling, medication interaction prediction, and data analysis. The commercial segment is growing as a result of pharmaceutical and biotechnology businesses' substantial spending in research and development (R&D) activities. Computational biology solutions are being used by businesses more and more in order to obtain a competitive edge in drug discovery. The integration of data science and machine learning (ML) into drug development processes is leading to a higher adoption of computational biology techniques in commercial settings.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest computational biology market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for computational biology.

North America is home to many leading pharmaceutical and biotechnology companies. The demand for computational biology solutions is significant in this region, as companies seek to streamline drug discovery and enhance their research and development (R&D) processes. The presence of well-established research institutions, universities, and laboratories equipped with advanced technologies fosters a conducive environment for computational biology. These institutions often collaborate with commercial entities, further driving the demand for computational services. Furthermore, top players in the region are developing new tools and methodologies that enhance research capabilities.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Certara, Chemical Computing Group ULC, Compugen Ltd, Dassault Systemes, Genedata AG, Insilico Biotechnology AG, Instem plc, Nimbus Therapeutics LLC, Schrodinger Inc. and Simulations Plus Inc.

Key Questions Answered in This Report

• 1.What was the size of the global computational biology market in 2024?
• 2.What is the expected growth rate of the global computational biology market during 2025-2033?
• 3.What are the key factors driving the global computational biology market?
• 4.What has been the impact of COVID-19 on the global computational biology market?
• 5.What is the breakup of the global computational biology market based on the application?
• 6.What is the breakup of the global computational biology market based on the services?
• 7.What is the breakup of the global computational biology market based on the end use?
• 8.What are the key regions in the global computational biology market?
• 9.Who are the key players/companies in the global computational biology market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Computational Biology Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Application

• 6.1 Cellular and Biological Simulation
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Computational Genomics
    • 6.1.2.2 Computational Proteomics
    • 6.1.2.3 Pharmacogenomics
    • 6.1.2.4 Others
  • 6.1.3 Market Forecast
• 6.2 Drug Discovery and Disease Modelling
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Target Identification
    • 6.2.2.2 Target Validation
    • 6.2.2.3 Lead Discovery
    • 6.2.2.4 Lead Optimization
  • 6.2.3 Market Forecast
• 6.3 Preclinical Drug Development
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Pharmacokinetics
    • 6.3.2.2 Pharmacodynamics
  • 6.3.3 Market Forecast
• 6.4 Clinical Trials
  • 6.4.1 Market Trends
  • 6.4.2 Key Segments
    • 6.4.2.1 Phase I
    • 6.4.2.2 Phase II
    • 6.4.2.3 Phase III
  • 6.4.3 Market Forecast
• 6.5 Human Body Simulation Software
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Services

• 7.1 In-house
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Contract
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Academics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Pharmaceutical Industry
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Commercial
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Certara
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Chemical Computing Group ULC
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Compugen Ltd
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Dassault Systemes
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Genedata AG
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Insilico Biotechnology AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Instem plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
  • 14.3.8 Nimbus Therapeutics LLC
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Schrodinger Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Simulations Plus Inc.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials